瑞舒伐他汀对急性冠脉综合征患者血清IMA及hs-CRP的影响  

Effect of rosuvastatin on serum level of ischemia modified albumin and high sensitivity C-reactive protein in patients with acute coronary syndrome

作　　者：赵文娟[1] 李庆民[1] 孙广利[1] 王强[1] 

机构地区：[1]河南平顶山市第一人民医院心内三科,平顶山467000

出　　处：《中国实用神经疾病杂志》2012年第1期22-24,共3页Chinese Journal of Practical Nervous Diseases

摘　　要：目的探讨不同剂量的瑞舒伐他汀对急性冠脉综合征(ACS)患者血清缺血修饰清蛋白(IMA)和超敏C反应蛋白(hs-CRP)水平的影响。方法将诊断为急性冠脉综合征患者96例随机分为瑞舒伐他汀常规治疗组(10mg/d)和强化治疗组(20mg/d),同时给予常规治疗,观察治疗前后2组血清IMA、hs-CRP水平的变化。结果治疗2周后2组ACS患者血清IMA、hs-CRP、血脂水平明显下降;与常规治疗组相比,强化治疗组效果更为明显,差异均有统计学意义(P<0.01)。结论强化瑞舒伐他汀治疗能显著降低ACS患者血清缺血修饰清蛋白、超敏C反应蛋白水平,抑制斑块内炎症反应,在ACS的早期诊断中有重要价值,可作为诊断早期ACS的敏感指标。Objective To investigate the effect of rosuvastatin on plasma ischemia modified albumin（IMA） and high-sensitivity C-reactive protein（hs-CRP） in patients with acute coronary syndrome（ACS）.Methods Ninety-six patients with ACS were randomly divided into conventional therapy group and intensive therapy group.Plasma was measured before and after therapy.Results The levels of IMA and hs-CRP were significantly lower after two weeks＇ treatment in the two groups,the levels of IMA and hs-CRP in intensive group were significantly lower than those in conventional therapy group（P0.01）.Conclusion Strengthening rosuvastatin treatment in patients with ACS can significantly reduce serum levels of IMA and hs-CRP,and inhibit plaque inflammation.Serum levels of IMA and hs-CRP have important values in the early diagnosis of ACS,and can be used as a sensitive indicator.

关 键 词：瑞舒伐他汀 急性冠脉综合征 IMA HS-CRP 

分 类 号：R543.3[医药卫生—心血管疾病]